Erickson John J, Rogers Meredith C, Hastings Andrew K, Tollefson Sharon J, Williams John V
Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232; and.
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232.
J Immunol. 2014 Nov 15;193(10):5108-17. doi: 10.4049/jimmunol.1302208. Epub 2014 Oct 22.
Reinfections with respiratory viruses are common and cause significant clinical illness, yet precise mechanisms governing this susceptibility are ill defined. Lung Ag-specific CD8(+) T cells (T(CD8)) are impaired during acute viral lower respiratory infection by the inhibitory receptor programmed death-1 (PD-1). To determine whether PD-1 contributes to recurrent infection, we first established a model of reinfection by challenging B cell-deficient mice with human metapneumovirus (HMPV) several weeks after primary infection, and found that HMPV replicated to high titers in the lungs. A robust secondary effector lung TCD8 response was generated during reinfection, but these cells were more impaired and more highly expressed the inhibitory receptors PD-1, LAG-3, and 2B4 than primary T(CD8). In vitro blockade demonstrated that PD-1 was the dominant inhibitory receptor early after reinfection. In vivo therapeutic PD-1 blockade during HMPV reinfection restored lung T(CD8) effector functions (i.e., degranulation and cytokine production) and enhanced viral clearance. PD-1 also limited the protective efficacy of HMPV epitope-specific peptide vaccination and impaired lung T(CD8) during heterotypic influenza virus challenge infection. Our results indicate that PD-1 signaling may contribute to respiratory virus reinfection and evasion of vaccine-elicited immune responses. These results have important implications for the design of effective vaccines against respiratory viruses.
呼吸道病毒再感染很常见,并会引发严重的临床疾病,但导致这种易感性的精确机制仍不清楚。在急性病毒性下呼吸道感染期间,肺抗原特异性CD8(+) T细胞(T(CD8))会受到抑制性受体程序性死亡1(PD-1)的损害。为了确定PD-1是否促成再感染,我们首先建立了一个再感染模型,在初次感染数周后用人偏肺病毒(HMPV)攻击B细胞缺陷小鼠,发现HMPV在肺中复制到高滴度。再感染期间产生了强大的继发性效应肺TCD8反应,但这些细胞比原发性T(CD8) 细胞受损更严重,且更高水平地表达抑制性受体PD-1、LAG-3和2B4。体外阻断实验表明,PD-1是再感染后早期的主要抑制性受体。在HMPV再感染期间进行体内治疗性PD-1阻断可恢复肺T(CD8) 效应功能(即脱颗粒和细胞因子产生)并增强病毒清除。PD-1还限制了HMPV表位特异性肽疫苗接种的保护效果,并在异型流感病毒攻击感染期间损害肺T(CD8) 细胞。我们的结果表明,PD-1信号传导可能促成呼吸道病毒再感染以及逃避疫苗引发的免疫反应。这些结果对设计针对呼吸道病毒的有效疫苗具有重要意义。